MWNA
RLAY icon

Marshall Wace North America’s Relay Therapeutics RLAY Stock Holding History

Marshall Wace North America’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$208K Buy
+6,600
New +$222K ﹤0.01% 1318
2021
Q2 		– Sell
-193,703
Closed -$6.7M – 1721
2021
Q1 		$6.7M Buy
+193,703
New +$8.41M 0.03% 488

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace North America's RLAY Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Relay Therapeutics (RLAY) in Q3 2021: 6,600 shares worth $208K. The stake represents ﹤0.01% of the portfolio and ranks #1318 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in RLAY as recently as Q1 2021.

Marshall Wace North America first reported a position in RLAY in Q1 2021 and has held it in 2 quarters since. The position peaked at $6.7M in Q1 2021. 132 funds tracked by Wall St. Rank hold RLAY as of Q3 2021.

  • Marshall Wace North America held 6,600 shares of Relay Therapeutics worth $208K as of Q3 2021.
  • Relay Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Relay Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1318 holding.
  • Marshall Wace North America first reported a position in Relay Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • Marshall Wace North America's Relay Therapeutics position peaked at $6.7M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.